Main Menu

Publications

Dr Nuria Porta

Publications Highlights View all by category

Types of Publications


Journal Articles

Hall, E. Hussain, S.A. Porta, N. Lewis, R. Crundwell, M. Jenkins, P. Rawlings, C. Tremlett, J. Sreenivasan, T. Wallace, J. Syndikus, I. Sheehan, D. Lydon, A. Huddart, R. James, N. BC2001 Investigators, (2022). Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. , , pp. S0302-2838(22)02265.  show abstract

Bundred, N. Porta, N. Brunt, A.M. Cramer, A. Hanby, A. Shaaban, A.M. Rakha, E.A. Armstrong, A. Cutress, R.I. Dodwell, D. Emson, M.A. Evans, A. Hartup, S.M. Horgan, K. Miller, S.E. McIntosh, S.A. Morden, J.P. Naik, J. Narayanan, S. Ooi, J. Skene, A.I. Cameron, D.A. Bliss, J.M. (2022). Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical cancer research : an official journal of the american association for cancer research, .  show abstract

Rescigno, P. Gurel, B. Pereira, R. Crespo, M. Rekowski, J. Rediti, M. Barrero, M. Mateo, J. Bianchini, D. Messina, C. Fenor de la Maza, M.D. Chandran, K. Carmichael, J. Guo, C. Paschalis, A. Sharp, A. Seed, G. Figueiredo, I. Lambros, M. Miranda, S. Ferreira, A. Bertan, C. Riisnaes, R. Porta, N. Yuan, W. Carreira, S. de Bono, J.S. (2021). Characterizing CDK12-Mutated Prostate Cancers. Clinical cancer research : an official journal of the american association for cancer research, Vol.27 (2), pp. 566-574.  show abstract

Messiou, C. Porta, N. Sharma, B. Levine, D. Koh, D.-. Boyd, K. Pawlyn, C. Riddell, A. Downey, K. Croft, J. Morgan, V. Stern, S. Cheung, B. Kyriakou, C. Kaczmarek, P. Winfield, J. Blackledge, M. Oyen, W.J. Kaiser, M.F. (2021). Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology: imaging cancer, Vol.3 (5), pp. e210048-e210048.

Hussain, S.A. Porta, N. Hall, E. Salawu, A. Lewis, R. Sreenivasan, T. Wallace, J. Crundwell, M. Jenkins, P. Tremlett, J. Huddart, R. James, N.D. BC2001 Investigators, (2021). Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. European urology, Vol.79 (2), pp. 307-315.  show abstract

Choudhury, A. Porta, N. Hall, E. Song, Y.P. Owen, R. MacKay, R. West, C.M. Lewis, R. Hussain, S.A. James, N.D. Huddart, R. Hoskin, P. BC2001 and BCON investigators, (2021). Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet oncol, Vol.22 (2), pp. 246-255.  show abstract

Winfield, J.M. Wakefield, J.C. Brenton, J.D. AbdulJabbar, K. Savio, A. Freeman, S. Pace, E. Lutchman-Singh, K. Vroobel, K.M. Yuan, Y. Banerjee, S. Porta, N. Ahmed Raza, S.E. deSouza, N.M. (2021). Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. British journal of cancer, .  show abstract

McHugh, D.J. Porta, N. Little, R.A. Cheung, S. Watson, Y. Parker, G.J. Jayson, G.C. O'Connor, J.P. (2021). Image Contrast, Image Pre-Processing, and T1 Mapping Affect MRI Radiomic Feature Repeatability in Patients with Colorectal Cancer Liver Metastases. Cancers, Vol.13 (2).  show abstract

Mariam, N.B. Song, Y.P. Joseph, N. Hoskin, P. Reeves, K. Porta, N. James, N. Choudhury, A. (2021). Hypofractionation: less is more?. Oncotarget, Vol.12 (17), pp. 1729-1733.  show abstract

Carreira, S. Porta, N. Arce-Gallego, S. Seed, G. Llop-Guevara, A. Bianchini, D. Rescigno, P. Paschalis, A. Bertan, C. Baker, C. Goodall, J. Miranda, S. Riisnaes, R. Figueiredo, I. Ferreira, A. Pereira, R. Crespo, M. Gurel, B. Nava Rodrigues, D. Pettitt, S.J. Yuan, W. Serra, V. Rekowski, J. Lord, C.J. Hall, E. Mateo, J. de Bono, J.S. (2021). Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer discovery, .  show abstract

Mateo, J. Porta, N. Bianchini, D. McGovern, U. Elliott, T. Jones, R. Syndikus, I. Ralph, C. Jain, S. Varughese, M. Parikh, O. Crabb, S. Robinson, A. McLaren, D. Birtle, A. Tanguay, J. Miranda, S. Figueiredo, I. Seed, G. Bertan, C. Flohr, P. Ebbs, B. Rescigno, P. Fowler, G. Ferreira, A. Riisnaes, R. Pereira, R. Curcean, A. Chandler, R. Clarke, M. Gurel, B. Crespo, M. Nava Rodrigues, D. Sandhu, S. Espinasse, A. Chatfield, P. Tunariu, N. Yuan, W. Hall, E. Carreira, S. de Bono, J.S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The lancet. oncology, Vol.21 (1), pp. 162-174.  show abstract

Huddart, R.A. Hall, E. Lewis, R. Porta, N. Crundwell, M. Jenkins, P.J. Rawlings, C. Tremlett, J. Campani, L. Hendron, C. Hussain, S.A. James, N.D. BC2001 Investigators, (2020). Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. European urology, Vol.77 (2), pp. 260-268.  show abstract

Mateo, J. Seed, G. Bertan, C. Rescigno, P. Dolling, D. Figueiredo, I. Miranda, S. Nava Rodrigues, D. Gurel, B. Clarke, M. Atkin, M. Chandler, R. Messina, C. Sumanasuriya, S. Bianchini, D. Barrero, M. Petermolo, A. Zafeiriou, Z. Fontes, M. Perez-Lopez, R. Tunariu, N. Fulton, B. Jones, R. McGovern, U. Ralph, C. Varughese, M. Parikh, O. Jain, S. Elliott, T. Sandhu, S. Porta, N. Hall, E. Yuan, W. Carreira, S. de Bono, J.S. (2020). Genomics of lethal prostate cancer at diagnosis and castration resistance. The journal of clinical investigation, Vol.130 (4), pp. 1743-1751.  show abstract

Kolinsky, M.P. Rescigno, P. Bianchini, D. Zafeiriou, Z. Mehra, N. Mateo, J. Michalarea, V. Riisnaes, R. Crespo, M. Figueiredo, I. Miranda, S. Nava Rodrigues, D. Flohr, P. Tunariu, N. Banerji, U. Ruddle, R. Sharp, A. Welti, J. Lambros, M. Carreira, S. Raynaud, F.I. Swales, K.E. Plymate, S. Luo, J. Tovey, H. Porta, N. Slade, R. Leonard, L. Hall, E. de Bono, J.S. (2020). A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Annals of oncology : official journal of the european society for medical oncology, Vol.31 (5), pp. 619-625.  show abstract

Mostafid, A.H. Porta, N. Cresswell, J. Griffiths, T.R. Kelly, J.D. Penegar, S.R. Davenport, K. McGrath, J.S. Campain, N. Cooke, P. Masood, S. Knowles, M.A. Feber, A. Knight, A. Catto, J.W. Lewis, R. Hall, E. (2020). CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. Bju international, Vol.125 (6), pp. 817-826.  show abstract

Cox, E. Saramago, P. Kelly, J. Porta, N. Hall, E. Tan, W.S. Sculpher, M. Soares, M. (2020). Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical genitourinary cancer, Vol.18 (4), pp. e418-e442.  show abstract

Syndikus, I. Cruickshank, C. Staffurth, J. Tree, A. Henry, A. Naismith, O. Mayles, H. Snelson, N. Hassan, S. Brown, S. Porta, N. Griffin, C. Hall, E. (2020). PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). Clinical and translational radiation oncology, Vol.25, pp. 22-28.  show abstract

Kelly, J.D. Tan, W.S. Porta, N. Mostafid, H. Huddart, R. Protheroe, A. Bogle, R. Blazeby, J. Palmer, A. Cresswell, J. Johnson, M. Brough, R. Madaan, S. Andrews, S. Cruickshank, C. Burnett, S. Maynard, L. Hall, E. BOXIT Investigators, (2019). BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European urology, Vol.75 (4), pp. 593-601.  show abstract

Cullen, M. Huddart, R. Joffe, J. Gardiner, D. Maynard, L. Hutton, P. Mazhar, D. Shamash, J. Wheater, M. White, J. Goubar, A. Porta, N. Witts, S. Lewis, R. Hall, E. 111 Trial Management Group, (2019). The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. European urology, .  show abstract

Haviland, J.S. Mannino, M. Griffin, C. Porta, N. Sydenham, M. Bliss, J.M. Yarnold, J.R. START Trialists' Group, (2018). Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiotherapy and oncology : journal of the european society for therapeutic radiology and oncology, Vol.126 (1), pp. 155-162.  show abstract

Cheang, M.C. Bliss, J.M. Viale, G. Speirs, V. Palmieri, C. Shaaban, A. Lønning, P.E. Morden, J. Porta, N. Jassem, J. van De Velde, C.J. Rasmussen, B.B. Verhoeven, D. Bartlett, J.M. Coombes, R.C. PathIES Sub-Committee, (2018). Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast cancer research and treatment, Vol.168 (1), pp. 169-178.  show abstract

Lorente, D. Ravi, P. Mehra, N. Pezaro, C. Omlin, A. Gilman, A. Miranda, M. Rescigno, P. Kolinsky, M. Porta, N. Bianchini, D. Tunariu, N. Perez, R. Mateo, J. Payne, H. Terstappen, L. IJzerman, M. Hall, E. de Bono, J. (2018). Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European urology focus, Vol.4 (2), pp. 235-244.  show abstract

Franco, P. Porta, N. Holliday, J.D. Willett, P. (2017). Molecular similarity considerations in the licensing of orphan drugs. Drug discovery today, Vol.22 (2), pp. 377-381.  show abstract

Choudhury, A. West, C.M. Porta, N. Hall, E. Denley, H. Hendron, C. Lewis, R. Hussain, S.A. Huddart, R. James, N. (2017). The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British journal of cancer, Vol.116 (5), pp. 649-657.  show abstract

Perez-Lopez, R. Mateo, J. Mossop, H. Blackledge, M.D. Collins, D.J. Rata, M. Morgan, V.A. Macdonald, A. Sandhu, S. Lorente, D. Rescigno, P. Zafeiriou, Z. Bianchini, D. Porta, N. Hall, E. Leach, M.O. de Bono, J.S. Koh, D.-. Tunariu, N. (2017). Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, Vol.283 (1), pp. 168-177.  show abstract

Goodall, J. Mateo, J. Yuan, W. Mossop, H. Porta, N. Miranda, S. Perez-Lopez, R. Dolling, D. Robinson, D.R. Sandhu, S. Fowler, G. Ebbs, B. Flohr, P. Seed, G. Rodrigues, D.N. Boysen, G. Bertan, C. Atkin, M. Clarke, M. Crespo, M. Figueiredo, I. Riisnaes, R. Sumanasuriya, S. Rescigno, P. Zafeiriou, Z. Sharp, A. Tunariu, N. Bianchini, D. Gillman, A. Lord, C.J. Hall, E. Chinnaiyan, A.M. Carreira, S. de Bono, J.S. TOPARP-A investigators, (2017). Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer discovery, Vol.7 (9), pp. 1006-1017.  show abstract

Martínez-Momblán, M.A. Gómez, C. Santos, A. Porta, N. Esteve, J. Úbeda, I. Halperin, I. Campillo, B. Guillaumet, M. Webb, S.M. Resmini, E. (2016). A specific nursing educational program in patients with Cushing’s syndrome. Endocrine, Vol.53 (1), pp. 199-209.

Wilkins, A. Furness, A. Corbett, R.W. Bloomfield, A. Porta, N. Morris, S. Ali, Z. Larkin, J. Harrington, K. (2015). The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. British journal of cancer, Vol.113 (9), pp. 1275-1281.  show abstract

Lincker, H. Ziogas, C. Carr, M. Porta, N. Eichler, H.-. (2014). Where do new medicines originate from in the EU?. Nature reviews drug discovery, Vol.13 (2), pp. 92-93.

Pedrós, C. Quintana, B. Rebolledo, M. Porta, N. Vallano, A. Arnau, J.M. (2014). Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. European journal of clinical pharmacology, Vol.70 (3), pp. 361-367.

Coelho, S. Ortíz, F. Gelpi, R. Koskinen, P. Porta, N. Bestard, O. Melilli, E. Taco, O. Torras, J. Honkanen, E. Grinyó, J.M. Cruzado, J.M. (2014). Sterile Leukocyturia Is Associated With Interstitial Fibrosis and Tubular Atrophy in Kidney Allograft Protocol Biopsies. American journal of transplantation, Vol.14 (4), pp. 908-915.

Franco, P. Porta, N. Holliday, J.D. Willett, P. (2014). The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation. Journal of cheminformatics, Vol.6 (1).  show abstract

Yildirim, T. Yilmaz, R. Altindal, M. Turkmen, E. Arici, M. Altun, B. Erdem, Y. Guliyev, O. Erkmen Uyar, M. Tutal, E. Bal, Z. Sezer, S. Erkmen Uyar, M. Bal, U. Bal, Z. Tutal, E. Say n, B. Guliyev, O. Erdemir, B. Sezer, S. O'Rourke-Potowki, A. Gauge, N. Penny, H. Cronin, A. Frame, S. Goldsmith, D.J. Yagan, J.A. Chandraker, A. Velickovic Radovanovic, R.M. Catic Djordjevic, A. Mitic, B. Stefanovic, N. Cvetkovic, T. Serpieri, N. Grosjean, F. Sileno, G. Torreggiani, M. Esposito, V. Mangione, F. Abelli, M. Castoldi, F. Catucci, D. Esposito, C. Dal Canton, A. Vatazin, A.V. Zulkarnaev, A.B. Borst, C. Liu, Y. Thoning, J. Tepel, M. Libetta, C. Margiotta, E. Borettaz, I. Canevari, M. Martinelli, C. Lainu, E. Abelli, M. Meloni, F. Sepe, V. Dal Canton, A. Miguel Costa, R. Vasquez Martul, E. Reboredo, J. Rivera, C. Simonato, F. Tognarelli, G. Daidola, G. Gallo, E. Burdese, M. Cantaluppi, V. Biancone, L. Segoloni, G.P. Burdese, M. Priora, M. Messina, M. Tamagnone, M. Daidola, G. Linsalata, A. Lavacca, A. Biancone, L. Segoloni, G. Zuidema, W. Erdman, R. van de Wetering, J. Dor, F. Roodnat, J. Massey, E. Timmerman, L. IJzermans, J. Weimar, W. Goldsmith, D.J. Sibley-Allen, C. Hilton, R. Moghul, M. Burnapp, L. Blake, G. Koo, T.Y. Park, J.-. Park, H.C. Kim, G.-. Lee, C.H. Oh, I.H. Kang, C.M. Hwang, J.K. Park, S.C. Choi, B.S. Chun, H.J. Kim, J.I. Yang, C.W. Moon, I.S. Van Laecke, S. Van Biesen, W. Nagler, E.V. Taes, Y. Peeters, P. Vanholder, R. Pruthi, R. Ravanan, R. Casula, A. Harber, M. Roderick, P. Fogarty, D. Cho, A. Shin, J.-. Jang, H.R. Lee, J.E. Huh, W. Kim, D.J. Oh, H.Y. Kim, Y.-. Sancho Calabuig, A. Gavela Martinez, E. Kanter Berga, J. Beltran Catalan, S. Avila Bernabeu, A.I. Pallardo Mateu, L.M. Gonzalez, E. Polanco, N. Molina, M. Gutierrez, E. Garcia Puente, L. Sevillano, A. Morales, E. Praga, M. Andres, A. Banasik, M. Boratynska, M. Koscielska-Kasprzak, K. Bartoszek, D. Myszka, M. Zmonarski, S. Nowakowska, B. Wawrzyniak, E. Halon, A. Chudoba, P. Klinger, M. Rojas-Rivera, J. Gonzalez, E. Polanco, N. Morales, E. Andres, A. Morales, J.M. Egido, J. Praga, M. Kopecky, C.M. Haidinger, M. Kaltenecker, C. Antlanger, M. Marsche, G. Holzer, M. Kovarik, J. Werzowa, J. Hecking, M. Saemann, M.D. Hwang, J.K. Kim, J.M. Koh, E.S. Chung, B.H. Park, S.C. Choi, B.S. Kim, J.I. Yang, C.W. Kim, Y.S. Moon, I.S. Banasik, M. Boratynska, M. Koscielska-Kasprzak, K. Krajewska, M. Mazanowska, O. Kaminska, D. Bartoszek, D. Zabinska, M. Halon, A. Malkiewicz, B. Patrzalek, D. Klinger, M. Sulowicz, J. Szostek, S. Wojas-Pelc, A. Ignacak, E. Sulowicz, W. Bellizzi, V. Calella, P. Cupisti, A. Capitanini, A. D'Alessandro, C. Giannese, D. Camocardi, A. Conte, G. Barsotti, M. Bilancio, G. Luciani, R. Locsey, L. Seres, I. Kovacs, D. Asztalos, L. Paragh, G. Wohlfahrtova, M. Balaz, P. Rokosny, S. Wohlfahrt, P. Bartonova, A. Viklicky, O. Kers, J. Geskus, R.B. Meijer, L.J. Bemelman, F. ten Berge, I.J. Florquin, S. Hwang, J.-. Jiang, M.-. Lu, Y.-. Weng, S.-. Testa, A. Porto, G. Sanguedolce, M. Spoto, B. Parlongo, R. Pisano, A. Enia, G. Tripepi, G. Zoccali, C. Zuidema, W. Mamode, N. Lennerling, A. Citterio, F. Massey, E. Van Assche, K. Sterckx, S. Frunza, M. Jung, H. Pascalev, A. Johnson, R. Loven, C. Weimar, W. Dor, F. Soleymanian, T. Keyvani, H. Jazayeri, S.M. Fazeli, Z. Ghamari, S. Mahabadi, M. Chegeni, V. Najafi, I. Ganji, M.R. Meys, K.M. Groothoff, J.W. Jager, K. Schaefer, F. Tonshoff, B. Mota, C. Cransberg, K. van Stralen, K. Gurluler, E. Gures, N. Alim, A. Gurkan, A. Cakir, U. Berber, I. Van Laecke, S. Caluwe, R. Nagler, E. Van Biesen, W. Peeters, P. Van Vlem, B. Vanholder, R. Sulowicz, J. Wojas-Pelc, A. Ignacak, E. Betkowska-Prokop, A. Kuzniewski, M. Krzanowski, M. Sulowicz, W. Masson, I. Flamant, M. Maillard, N. Cavalier, E. Moranne, O. Alamartine, E. Mariat, C. Delanaye, P. Canas Sole, L.L. Iglesias Alvarez, E. Pastor, M.C. Moreno Flores, F.F. Abujder, V.V. Graterol, F.F. Bonet Sol, J.J. Lauzurica Valdemoros, R.R. Yoshikawa, M. Kitamura, K. Nakai, K. Goto, S. Fujii, H. Ishimura, T. Takeda, M. Fujisawa, M. Nishi, S. Prasad, N. Gurjer, D. Bhadauria, D. Gupta, A. Sharma, R. Kaul, A. Cybulla, M. West, M. Nicholls, K. Torras, J. Sunder-Plassmann, G. Feriozzi, S. Lo, S. Wong, P.Y. Ip, D. Wong, C.K. Chow, V.C. Mo, S.K. Molnar, M. Ujszaszi, A. Czira, M.E. Novak, M. Mucsi, I. Cruzado, J.M. Coelho, S. Porta, N. Bestard, O. Melilli, E. Taco, O. Rivas, I. Grinyo, J. Pouteau, L.-. N'Guyen, J.-. Hami, A. Hourmant, M. Ghahramani, N. Karparvar, Z. Shadrou, S. Ghahramani, M. Fauvel, J.P. Hadj-Aissa, A. Buron, F. Morelon, E. Ducher, M. Heine, C. Glander, P. Neumayer, H.-. Budde, K. Liefeldt, L. Montero, N. Webster, A.C. Royuela, A. Zamora, J. Crespo, M. Pascual, J. Adema, A.Y. van Dorp, W.T. Mallat, M.J. de Fijter, H.W. Kim, Y.S. Hong, Y.A. Chung, B.H. Park, C.W. Yang, C.W. Kim, Y.-. Choi, B.S. Suleymanlar, G. Uzundurukan, Z. Kapuagas, A. Sencan, I. Akdag, R. Pascual, J. Torio, A. Mas, V. Perez-Saez, M.J. Mir, M. Faura, A. Montes-Ares, O. Checa, M.D. Crespo, M. Sawinski, D. Trofe-Clark, J. Sparkes, T. Patel, P. Goral, S. Bloom, R. Kim, H.J. Park, S.J. Kim, T.H. Kim, Y.W. Kim, Y.H. Kang, S.W. Abdel Halim, M. Gheith, O. Al-Otaibi, T. Mosaad, A. Awadeen, W. Said, T. Nair, P. Nampoory, M.R. (2013). Transplantation: clinical studies - A. Nephrology dialysis transplantation, Vol.28 (suppl 1), pp. i275-i292.

Muñoz, L. Moure, R. Porta, N. Gonzalez, L. Guerra, R. Alcaide, F. Santin, M. (2013). GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries?. Diagnostic microbiology and infectious disease, Vol.75 (3), pp. 325-326.

Fernández-Lorente, L. Riera, L. Bestard, O. Carrera, M. Gomà, M. Porta, N. Torras, J. Melilli, E. Gil-Vernet, S. Grinyó, J.M. Cruzado, J.M. (2012). Long-Term Results of Biopsy-Guided Selection and Allocation of Kidneys From Older Donors in Older Recipients. American journal of transplantation, Vol.12 (10), pp. 2781-2788.

Porta, N. Calle, M.L. Malats, N. Gómez, G. (2012). A dynamic model for the risk of bladder cancer progression. Statistics in medicine, Vol.31 (3), pp. 287-300.

Porta, N. Bonet, C. Cobo, E. (2007). Discordance between reported intention-to-treat and per protocol analyses. Journal of clinical epidemiology, Vol.60 (7), pp. 663-669.

Mateo, J. Carreira, S. Sandhu, S. Miranda, S. Mossop, H. Perez-Lopez, R. Nava Rodrigues, D. Robinson, D. Omlin, A. Tunariu, N. Boysen, G. Porta, N. Flohr, P. Gillman, A. Figueiredo, I. Paulding, C. Seed, G. Jain, S. Ralph, C. Protheroe, A. Hussain, S. Jones, R. Elliott, T. McGovern, U. Bianchini, D. Goodall, J. Zafeiriou, Z. Williamson, C.T. Ferraldeschi, R. Riisnaes, R. Ebbs, B. Fowler, G. Roda, D. Yuan, W. Wu, Y.M. Cao, X. Brough, R. Pemberton, H. A'Hern, R. Swain, A. Kunju, L.P. Eeles, R. Attard, G. Lord, C.J. Ashworth, A. Rubin, M.A. Knudsen, K.E. Feng, F.Y. Chinnaiyan, A.M. Hall, E. de Bono, J.S. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The new england journal of medicine, Vol.373 (18), pp. 1697-1708.  show abstract

Bliss, J. Porta, N. Toms, C. Banerjee, S. Stewart, J. Natrajan, R. Lord, C. ATARI trial: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). International journal of gynecological cancer, .

Bliss, J. Porta, N. Emson, M. Miller, S. Morden, J. Combined Peri-operative Lapatinib and Trastuzumab in Early HER2 Positive Breast Cancer can Identify Early Responders: Results from the UK EPHOS-B Trial (CRUK/08/002. Clinical cancer research, .

Hall, E. Parr, H. Porta, N. Joint Models for Dynamic Prediction in Localised Prostate Cancer: A Literature Review. , .

Philipps, L. Hall, E. Porta, N. Hafeez, S. Huddart, R. James, N. Correlation of clinician and patient reported outcomes in the BC2001 trial. , .


Conferences

Smith, T.A.West, C.M.Lane, B.Irlam-Jones, J.More, E.Mistry, H.Hoskin, P.J.Hussain, S.A.Hall, E.Porta, N.Huddart, R.A.James, N.D.Choudhury, A. (2022). 1734MO Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials, Annals of Oncology, Vol.33, p.S1330.

In this section

Publications